BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35290608)

  • 1. Autoimmune Neurological Disorders with IgG4 Antibodies: a Distinct Disease Spectrum with Unique IgG4 Functions Responding to Anti-B Cell Therapies.
    Dalakas MC
    Neurotherapeutics; 2022 Apr; 19(3):741-752. PubMed ID: 35290608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.
    Dalakas MC
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34845096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
    Briani C; Visentin A
    Neurotherapeutics; 2022 Apr; 19(3):874-884. PubMed ID: 35349079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.
    Cortese A; Lombardi R; Briani C; Callegari I; Benedetti L; Manganelli F; Luigetti M; Ferrari S; Clerici AM; Marfia GA; Rigamonti A; Carpo M; Fazio R; Corbo M; Mazzeo A; Giannini F; Cosentino G; Zardini E; Currò R; Gastaldi M; Vegezzi E; Alfonsi E; Berardinelli A; Kouton L; Manso C; Giannotta C; Doneddu P; Dacci P; Piccolo L; Ruiz M; Salvalaggio A; De Michelis C; Spina E; Topa A; Bisogni G; Romano A; Mariotto S; Mataluni G; Cerri F; Stancanelli C; Sabatelli M; Schenone A; Marchioni E; Lauria G; Nobile-Orazio E; Devaux J; Franciotta D
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31753915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
    Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
    Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.
    Zografou C; Vakrakou AG; Stathopoulos P
    Front Immunol; 2021; 12():686466. PubMed ID: 34220839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects.
    Manso C; Querol L; Mekaouche M; Illa I; Devaux JJ
    Brain; 2016 Jun; 139(Pt 6):1700-12. PubMed ID: 27017186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expanding field of IgG4-mediated neurological autoimmune disorders.
    Huijbers MG; Querol LA; Niks EH; Plomp JJ; van der Maarel SM; Graus F; Dalmau J; Illa I; Verschuuren JJ
    Eur J Neurol; 2015 Aug; 22(8):1151-61. PubMed ID: 26032110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growing Spectrum of Autoimmune Nodopathies.
    Gupta P; Mirman I; Shahar S; Dubey D
    Curr Neurol Neurosci Rep; 2023 May; 23(5):201-212. PubMed ID: 37014546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
    Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
    Front Immunol; 2020; 11():776. PubMed ID: 32547535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyradiculoneuropathy.
    Pascual-Goñi E; Fehmi J; Lleixà C; Martín-Aguilar L; Devaux J; Höftberger R; Delmont E; Doppler K; Sommer C; Radunovic A; Carvajal A; Smyth S; Williams L; Mazanec R; Potočková V; Hinds N; Cassereau J; Viala K; Lefilliatre M; Nicolas G; Foley P; Leypoldt F; Keddie S; Lunn MP; Zimprich F; Nunkoo VS; Löscher WN; Martínez-Martínez L; Díaz-Manera J; Rojas-Garcia R; Illa I; Rinaldi S; Querol L
    Brain; 2021 May; 144(4):1183-1196. PubMed ID: 33880507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neurofascin autoantibody and demyelination.
    Kira JI; Yamasaki R; Ogata H
    Neurochem Int; 2019 Nov; 130():104360. PubMed ID: 30582947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the depths of IgG4: insights into autoimmunity and novel treatments.
    Ünlü S; Sánchez Navarro BG; Cakan E; Berchtold D; Meleka Hanna R; Vural S; Vural A; Meisel A; Fichtner ML
    Front Immunol; 2024; 15():1346671. PubMed ID: 38698867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage.
    Appeltshauser L; Junghof H; Messinger J; Linke J; Haarmann A; Ayzenberg I; Baka P; Dorst J; Fisse AL; Grüter T; Hauschildt V; Jörk A; Leypoldt F; Mäurer M; Meinl E; Michels S; Motte J; Pitarokoili K; Stettner M; Villmann C; Weihrauch M; Welte GS; Zerr I; Heinze KG; Sommer C; Doppler K
    Brain; 2023 May; 146(5):1932-1949. PubMed ID: 36346134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement deposition induced by binding of anti-contactin-1 auto-antibodies is modified by immunoglobulins.
    Appeltshauser L; Weishaupt A; Sommer C; Doppler K
    Exp Neurol; 2017 Jan; 287(Pt 1):84-90. PubMed ID: 27746185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune nodopathies, an emerging diagnostic category.
    Martín-Aguilar L; Lleixà C; Pascual-Goñi E
    Curr Opin Neurol; 2022 Oct; 35(5):579-585. PubMed ID: 35989582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of monovalency on anti-contactin-1 IgG4.
    Taieb G; Jentzer A; Vegezzi E; Lleixà C; Illa I; Querol L; Devaux JJ
    Front Immunol; 2023; 14():1021513. PubMed ID: 36999029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4 autoimmune nodopathy.
    Kmezic I; Press R; Glenewinkel H; Doppler K; Appeltshauser L
    J Neuroimmunol; 2024 Apr; 389():578326. PubMed ID: 38422690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.